FDA approves applications for CV drug Ranexa (bizjournals.com via Yahoo! Finance)
CV Therapeutics Inc. said Monday the Food and Drug Administration accepted new drug and supplemental new drug applications for angina drug Ranexa.

Small Cap: Bionics to test anti-cancer drug on humans (Australasian Investment Review via Yahoo!7 Finance)
Shares in biotechnology company Bionomics Limited (BNO) climbed 7% to 37.5 cents after it said on Thursday its application to the US Food and Drug Administration (FDA) for its new anti-cancer compound has passed review. Trading volumes were thin, indicating investor caution as the process has a long way to go before it receives final approval for market distribution. The South Australian based ...

Targanta Revives Oritavancin: Next Weapon Against cSSSI? (BioWorld)
Remember FDA-stalled oritavancin? The hospital-based glycopeptide antibiotic acquired in 2001 by InterMune Inc . from Eli Lilly and Co . (which developed the compound as a replacement for vancomycin, which still takes an estimated 80 percent share of the market) was bought by Targanta Therapeutics Inc around Christmas four years later.